|
1
|
Travers JG, Kamal FA, Robbins J, Yutzey KE
and Blaxall BC: Cardiac fibrosis: The fibroblast awakens. Circ Res.
118:1021–1040. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Moore-Morris T, Guimarães-Camboa N, Yutzey
KE, Pucéat M and Evans SM: Cardiac fibroblasts: From development to
heart failure. J Mol Med (Berl). 93:823–830. 2015. View Article : Google Scholar
|
|
3
|
Lombardero M, Kovacs K and Scheithauer BW:
Erythropoietin: A hormone with multiple functions. Pathobiology.
78:41–53. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ma BX, Li J, Li H and Wu SS: Recombinant
human erythropoietin protects myocardial cells from apoptosis via
the janus-activated kinase 2/signal transducer and activator of
transcription 5 pathway in rats with epilepsy. Curr Ther Res Clin
Exp. 77:90–98. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Elshiekh M, Kadkhodaee M, Seifi B,
Ranjbaran M and Ahghari P: Ameliorative effect of recombinant human
erythropoietin and ischemic preconditioning on renal ischemia
reperfusion injury in rats. Nephrourol Mon. 7:e311522015.
View Article : Google Scholar
|
|
6
|
Noguchi T, Ohta S, Kakinoki R, Ikeguchi R,
Kaizawa Y, Oda H and Matsuda S: The neuroprotective effect of
erythropoietin on spinal motor neurons after nerve root avulsion
injury in rats. Restor Neurol Neurosci. 33:461–470. 2015.PubMed/NCBI
|
|
7
|
Nakamura S, Sho M, Koyama F, Ueda T,
Nishigori N, Inoue T, Nakamoto T, Fujii H, Yoshikawa S, Inatsugi N
and Nakajima Y: Erythropoietin attenuates intestinal inflammation
and promotes tissue regeneration. Scand J Gastroenterol.
50:1094–1102. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Geng XC, Hu ZP and Lian GY: Erythropoietin
ameliorates renal interstitial fibrosis via the inhibition of
fibrocyte accumulation. Mol Med Rep. 11:3860–3865. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Park SY, Lee JY, Tak WY, Kweon YO and Lee
MS: Erythropoietin decreases carbon tetrachloride-induced hepatic
fibrosis by inhibiting transforming growth factor-beta. Chin Med J
(Engl). 125:3098–3103. 2012.
|
|
10
|
Zhang XJ, Ma YX, Wen Y and Xu XJ:
Erythropoietin suppresses the expressions of TGF-beta1 and collagen
in rat cardiac fibroblasts induced by angiotensin II. Zhonghua Xin
Xue Guan Bing Za Zhi. 36:636–640. 2008.In Chinese. PubMed/NCBI
|
|
11
|
Wang LP, Yang XH, Wang XJ, Li SM, Sun N
and Zhang T: Erythropoietin decreases the occurrence of myocardial
fibrosis by inhibiting the NADPH-ERK-NF-x03BA;B pathway.
Cardiology. 133:97–108. 2016. View Article : Google Scholar
|
|
12
|
Tada H, Kagaya Y, Takeda M, Ohta J, Asaumi
Y, Satoh K, Ito K, Karibe A, Shirato K, Minegishi N and Shimokawa
H: Endogenous erythropoietin system in non-hematopoietic lineage
cells plays a protective role in myocardial ischemia/reperfusion.
Cardiovasc Res. 71:466–477. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jun JH, Jun NH, Shim JK, Shin EJ and Kwak
YL: Erythropoietin protects myocardium against ischemia-reperfusion
injury under moderate hyperglycemia. Eur J Pharmacol. 745:1–9.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lu J, Yao YY, Dai QM, Ma GS, Zhang SF, Cao
L, Ren LQ and Liu NF: Erythropoietin attenuates cardiac dysfunction
by increasing myocardial angiogenesis and inhibiting interstitial
fibrosis in diabetic rats. Cardiovasc Diabetol. 11:1052012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu S, Zhao C, Yang C, Li X, Huang H, Liu
N, Li S, Wang X and Liu J: Gambogic acid suppresses pressure
overload cardiac hypertrophy in rats. Am J Cardiovasc Dis.
3:227–238. 2013.PubMed/NCBI
|
|
16
|
Merkulov S, Chen X, Chandler MP and
Stelzer JE: In vivo cardiac myosin binding protein C gene transfer
rescues myofilament contractile dysfunction in cardiac myosin
binding protein C null mice. Circ Heart Fail. 5:635–644. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wei XL, Fang RT, Yang YH, Bi XY, Ren GX,
Luo AL, Zhao M and Zang WJ: Protective effects of extracts from
Pomegranate peels and seeds on liver fibrosisinduced by carbon
tetrachloride in rats. BMC Complement Altern Med. 15:3892015.
View Article : Google Scholar
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-delta delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
19
|
Chen CJ, He H, Luo Y, Zhou M, Yin D and He
M: Involvement of Bcl-2 Signal pathway in the protective effects of
apigenin on anoxia/reoxygenation-induced myocardium injury. J
Cardiovasc Pharmacol. 67:152–163. 2016. View Article : Google Scholar
|
|
20
|
Steward R, McNally FJ and Schedl P:
Isolation of the dorsal locus of Drosophila. Nature. 311:262–265.
1984. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Medzhitov R, Preston-Hurlburt P and
Janeway CA Jr: A human homologue of the Drosophila Toll protein
signals activation of adaptive immunity. Nature. 388:394–397. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang Y, Lv J, Jiang S, Ma Z, Wang D, Hu W,
Deng C, Fan C, Di S, Sun Y and Yi W: The emerging role of Toll-like
receptor 4 in myocardial inflammation. Cell Death Dis. 7:e22342016.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhao HW, Zhang ZF, Chai X, Li GQ, Cui HR,
Wang HB, Meng YK, Liu HM, Wang JB, Li RS, et al: Oxymatrine
attenuates CCl4-induced hepatic fibrosis via modulation of
TLR4-dependent inflammatory and TGF-β1 signaling pathways. Int
Immunopharmacol. 36:249–255. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang Y, Peng W, Ao X, Dai H, Yuan L,
Huang X and Zhou Q: TAK-242, a Toll-like receptor 4 antagonist,
protects against aldosterone-induced cardiac and renal injury. PLoS
One. 10:e01424562015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ma ZJ, Zhang XN, Li L, Yang W, Wang SS,
Guo X, Sun P and Chen LM: Tripterygium glycosides tablet
ameliorates renal tubulointerstitial fibrosis via the Toll-like
receptor 4/nuclear factor kappa B signaling pathway in high-fat
diet fed and streptozotocin-induced diabetic rats. J Diabetes Res.
2015:3904282015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yang HZ, Wang JP, Mi S, Liu HZ, Cui B, Yan
HM, Yan J, Li Z, Liu H, Hua F, et al: TLR4 activity is required in
the resolution of pulmonary inflammation and fibrosis after acute
and chronic lung injury. Am J Pathol. 180:275–292. 2012. View Article : Google Scholar
|
|
27
|
Qi W, Shen Q, Zhang L, Han LP and Wang S:
Study on the inflammatory intervention of erythropoietin on NEC.
Exp Ther Med. 11:2221–2224. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Glezeva N and Baugh JA: Role of
inflammation in the pathogenesis of heart failure with preserved
ejection fraction and its potential as a therapeutic target. Heart
Fail Rev. 19:681–694. 2014. View Article : Google Scholar
|
|
29
|
Zhang W, Lavine KJ, Epelman S, Evans SA,
Weinheimer CJ, Barger PM and Mann DL: Necrotic myocardial cells
release damage-associated molecular patterns that provoke
fibroblast activation in vitro and trigger myocardial inflammation
and fibrosis in vivo. J Am Heart Assoc. 4:e0019932015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Stifano G, Affandi AJ, Mathes AL, Rice LM,
Nakerakanti S, Nazari B, Lee J, Christmann RB and Lafyatis R:
Chronic Toll-like receptor 4 stimulation in skin induces
inflammation, macrophage activation, transforming growth factor
beta signature gene expression, and fibrosis. Arthritis Res Ther.
16:R1362014. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang Y, Wang JH, Zhang YY, Wang YZ, Wang
J, Zhao Y, Jin XX, Xue GL, Li PH, Sun YL, et al: Deletion of
interleukin-6 alleviated interstitial fibrosis in
streptozotocin-induced diabetic cardiomyopathy of mice through
affecting TGFβ1 and miR-29 pathways. Sci Rep. 6:230102016.
View Article : Google Scholar
|
|
32
|
Zhou SF, Yuan J, Liao MY, Xia N, Tang TT,
Li JJ, Jiao J, Dong WY, Nie SF, Zhu ZF, et al: IL-17A promotes
ventricular remodeling after myocardial infarction. J Mol Med
(Berl). 92:1105–1116. 2014. View Article : Google Scholar
|
|
33
|
Pulskens WP, Rampanelli E, Teske GJ,
Butter LM, Claessen N, Luirink IK, van der Poll T, Florquin S and
Leemans JC: TLR4 promotes fibrosis but attenuates tubular damage in
progressive renal injury. J Am Soc Nephrol. 21:1299–1308. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Turhan AH, Atici A, Muşlu N, Polat A and
Sungur MA: Erythropoietin may attenuate lung inflammation in a rat
model of meconium aspiration syndrome. Exp Lung Res. 42:199–204.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sifringer M, Genz K, Brait D, Brehmer F,
Löber R, Weichelt U, Kaindl AM, Gerstner B and Felderhoff-Mueser U:
Erythropoietin attenuates hyperoxia-induced cell death by
modulation of inflammatory mediators and matrix metalloproteinases.
Dev Neurosci. 31:394–402. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pang L, Zhang N, Dong N, Wang DW, Xu DH,
Zhang P and Meng XW: Erythropoietin protects rat brain injury from
carbon monoxide poisoning by inhibiting Toll-like receptor
4/NF-kappa B-dependent inflammatory responses. Inflammation.
39:561–568. 2016. View Article : Google Scholar
|
|
37
|
Santhanam AV, d'Uscio LV and Katusic ZS:
Cardiovascular effects of erythropoietin an update. Adv Pharmacol.
60:257–285. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Rong R and Xijun X: Erythropoietin
pretreatment suppresses inflammation by activating the PI3K/Akt
signaling pathway in myocardial ischemia-reperfusion injury. Exp
Ther Med. 10:413–418. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Dong H, Zhang X, Dai X, Lu S, Gui B, Jin
W, Zhang S, Zhang S and Qian Y: Lithium ameliorates
lipopolysaccharide-induced microglial activation via inhibition of
Toll-like receptor 4 expression by activating the PI3K/Akt/FoxO1
pathway. J Neuroinflammation. 14:140–144. 2014. View Article : Google Scholar
|
|
40
|
Wang J, Bai X, Song Q, Fan F, Hu Z, Cheng
G and Zhang Y: mir-223 inhibits lipid deposition and inflammation
by suppressing Toll-like receptor 4 signaling in macrophages. Int J
Mol Sci. 16:24965–24982. 2015. View Article : Google Scholar : PubMed/NCBI
|
